Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine

Panitumumab is a monoclonal antibody developed against the human epidermal growth factor receptor (EGFR). TAS‐102 is a novel chemotherapeutic agent containing trifluridine (FTD) as the active cytotoxic component. Both panitumumab and TAS‐102 have been approved for the treatment of metastatic colorec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Baba, Yuji, Tamura, Toshiya, Satoh, Yoshihiko, Gotou, Masamitsu, Sawada, Hiroshi, Ebara, Shunsuke, Shibuya, Kazunori, Soeda, Jumpei, Nakamura, Kazuhide
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5537908/
https://ncbi.nlm.nih.gov/pubmed/28486761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados